Phase Ii Clinical Trials

Earlier than Expected - DXB Gets First Regulatory Approval in Europe.

Next Investors Feb 01, 2022

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.